Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

G-Pen (Glucagon Injection) Compared to GlucaGen Hypokit (Glucagon) for Induced Hypoglycemia Rescue in Adults With T1D: A Phase 3 Multi-center, Randomized, Controlled, Single Blind, 2-way Crossover Study to Evaluate Efficacy and Safety

Trial Profile

G-Pen (Glucagon Injection) Compared to GlucaGen Hypokit (Glucagon) for Induced Hypoglycemia Rescue in Adults With T1D: A Phase 3 Multi-center, Randomized, Controlled, Single Blind, 2-way Crossover Study to Evaluate Efficacy and Safety

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 21 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glucagon (Primary)
  • Indications Hypoglycaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors XERIS Pharmaceuticals
  • Most Recent Events

    • 21 Nov 2019 According to a Xeris Pharmaceuticals media release, based on the results from this study, the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for liquid stable glucagon for the treatment of severe hypoglycemia in people with diabetes, to be delivered via pre-filled syringe or auto-injector routes of administration.
    • 17 Jun 2019 Results published in the Xeris Pharmaceuticals Media Release
    • 06 May 2019 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top